Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

计划入组 86 人 · 首次发布于 2022 年 4 月 4 日

Expression of IRAK1 Gene rs1059703-related Single- Nucleotide Polymorphisms in Egyptian Patient With Rheumatoid Arthritis

计划入组 90 人 · 首次发布于 2022 年 10 月 20 日

Neurobiology of Opioid Dependence: 4 - 4

首次发布于 1999 年 9 月 21 日

dual IRAK1/4 inhibitors (myelodysplastic Syndrome/acute myeloid leukemia)

Dual IRAK1/IRAK4 Inhibitor(Psivant Therapeutics)

Terpinen-4-ol

C₁₀H₁₈O

Xi'an No.4 Hospital

China

Guiyang No.4 People's Hospital

China

Huai'an No.4 People's Hospital

China

KME-0584: Novel IRAK1/4 Inhibitor Shows Promise in AML and HR-MDS Treatment

Rigel Pharmaceuticals Advances R289 Phase 1b Trial for Lower-Risk MDS with First Dose Expansion Patient

Rigel's R289 Shows Promise in Lower-Risk MDS with 33% Transfusion Independence Rate at ASH 2025